Skip to main content
Medpace Holdings, Inc. logo

Medpace Holdings, Inc. — Investor Relations & Filings

Ticker · MEDP ISIN · US58506Q1094 LEI · 549300H8TYEUVTW14A54 US Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2023-07-31 Director's Dealing
Country US United States of America
Listing US MEDP

About Medpace Holdings, Inc.

https://investor.medpace.com/

Medpace Holdings, Inc. is a scientifically-driven, global, full-service clinical contract research organization (CRO) that provides Phase I-IV clinical development services. The company serves the biotechnology, pharmaceutical, and medical device industries, with a mission to accelerate the development of safe and effective medical therapeutics. Medpace employs a disciplined operating approach that leverages regulatory and therapeutic expertise. Its services include clinical pharmacology, central laboratory, bioanalytical, ECG core lab, and imaging core labs. The company has expertise across major therapeutic areas, including oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective diseases.

Recent filings

Filing Released Lang Actions
Director's Dealing 2023
Director's Dealing
2023-07-31 English
Regulatory Filings 2023
Regulatory Filings
2023-07-31 English
Regulatory Filings 2023
Regulatory Filings
2023-07-27 English
10-Q
Interim / Quarterly Report Q2 2023
2023-07-25 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Medpace Holdings, Inc. It specifically states in Item 2.02 that the company issued a press release announcing financial results for the three and six months ended June 30, 2023. The document includes the press release as Exhibit 99.1 and clarifies that the information is furnished and not filed, indicating it is an announcement rather than the full financial report itself. The document length is 4022 characters, which is relatively short and consistent with a report publication announcement or a regulatory filing. Since this is a Form 8-K announcing financial results and furnishing a press release, it fits best under Regulatory Filings (RNS) rather than an Interim Report (IR) or Earnings Release (ER) because it is a formal SEC filing announcing the results rather than the full report or just a brief earnings highlight. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2023-07-24 English
Director's Dealing 2023
Director's Dealing
2023-07-05 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.